While traditional methods for treating cancer, including chemotherapy and radiation, are often effective at killing cancer cells, they can also kill healthy cells, as well. Cancer researchers around the world are searching for more effective therapies that do not compromise patients' long-term health and wellness. One of the most promising research areas is immunotherapy, which has shown great promise in treating many types of cancer.
Immunotherapies, including immune checkpoint modulators and cell therapy, have revolutionized the treatment of many human diseases. They have improved the outcomes of many cancers to a level thought impossible even a few years ago and comprise a new family of treatments that are quickly becoming a foundation of modern medicine. Classic immunotherapies such as vaccines are becoming increasingly important in a world threatened by emerging pathogens and antibodies that target discrete molecules have helped patients control various autoimmune ailments.
The Center for Immunotherapy & Precision Immuno-Oncology (CITI) is a state-of-the-art center dedicated to immunotherapy research, discovery and developmental therapeutics, with the ultimate goal to make precision immuno-oncology available for every patient. Learn more about our mission and goals.
Our program advances state-of-the-art cell engineering and T cell therapy developmental therapeutics, focusing on clinical development and research. We run cell therapy trials and develop new cell therapy approaches.
Our division advances translational immunology research, specializing in the fields of immuno-oncology, auto-immunity, computational immunology and population immunology.
Our program brings enhanced clinical trials correlates and discovery capabilities to Cleveland Clinic and Case Comprehensive Cancer Center for a wide range of basic and clinical topics.
Our program collaborates with the Cleveland Clinic Cancer Center and Case Comprehensive Cancer Center to provide precision approaches, including immunogenomic profiling, and new immunotherapy trials to patients and investigators.
Our program advances state-of-the-art cell engineering and T cell therapy developmental therapeutics, focusing on clinical development and research. We run cell therapy trials and develop new cell therapy approaches.Learn More
It is our ultimate goal to offer immunogenomic profiling to all patients receiving immunotherapy treatment, either through clinical trials or commercial treatments.Learn More
The Marcela Diaz lab studies the mechanisms that promote or inhibit anti-tumor immune responses and how they could be targeted with immunotherapies.Learn More
The goal of the Melenhorst lab is to develop potent, safe T cell-based gene therapies for hematologic and solid organ malignancies.Learn More
The Ni lab investigates alterations in metabolism-related genes and metabolites could have direct impact in cancer predisposition, tumor progression and immunotherapy treatment response.Learn More
The gift from the United Arab Emirates will advance cancer and pathogen research globally.
Precision cancer medicine is the goal of a new multidisciplinary study, led by Dr. Tim Chan, examining radiation therapy combined with targeted therapy
Dr. Tim Chan demonstrated that pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy.
Exciting investigation and groundbreaking discovery happens every day at Cleveland Clinic. Join our team of expert researchers at the Center for Immunotherapy & Precision Immuno-Oncology.View Careers